Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + Durvalumab in Chinese EGFR Wild-type NSCLC With MET Alteration (SOUND)
NCT05374603Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of savolitinib and durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 10 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
savolitinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05374603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374603.